When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
LXRX - Dosing underway in Lexicon Pharma's mid-stage LX9211 study in diabetic neuropathic pain
Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals (NASDAQ:LXRX)commences patient dosing with blinded study drug in its RELIEF-DPN-1, a Phase 2 study of LX9211 for the treatment of diabetic peripheral neuropathic pain.
More news on: Lexicon Pharmaceuticals, Inc., Healthcare stocks news,